Glycine vs Placebo for the Schizophrenia Prodrome

Phase 2/3 Completed 8 enrolled Yale University Glytech, Inc · collab National Alliance for Research on Schizophrenia and Depression · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.

Timeline

Start: 2006-03
Primary completion: 2009-07
Completion: 2009-07

Publications

Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. Eur Neuropsychopharmacol. 2013 Aug;23(8):931-40. doi: 10.1016/j.euroneuro.2012.09.008. Epub 2012 Oct 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Glycine	Other / unclassified	0.4 g/kg	—

Glycine vs Placebo for the Schizophrenia Prodrome

Summary

Timeline

Publications

Drugs

Indications